NCT01265992View on ClinicalTrials.gov

Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Secondary HyperparathyroidismChronic Kidney Disease
Trial Locations (10)

391 85

Site Reference ID/Investigator# 47723, Kalmar

651 85

Site Reference ID/Investigator# 41084, Karlstad

291 85

Site Reference ID/Investigator# 45190, Kristianstad

581 85

Site Reference ID/Investigator# 41085, Linköping

601 82

Site Reference ID/Investigator# 41087, Norrköping

701 85

Site Reference ID/Investigator# 45188, Örebro

541 85

Site Reference ID/Investigator# 41088, Skövde

112 81

Site Reference ID/Investigator# 57782, Stockholm

331 85

Site Reference ID/Investigator# 41089, Värnamo

721 89

Site Reference ID/Investigator# 45191, Västerås

Sponsors
All Listed Sponsors
collaborator

Pharma Consulting Group AB

INDUSTRY

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01265992 - Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis | Biotech Hunter | Biotech Hunter